Comparative Pharmacology
Head-to-head clinical analysis: FLUDEOXYGLUCOSE F18 versus NEUROLITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDEOXYGLUCOSE F18 versus NEUROLITE.
FLUDEOXYGLUCOSE F18 vs NEUROLITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fludeoxyglucose F18 is a glucose analog that is taken up by cells via glucose transporters (GLUT), particularly GLUT-1. It is phosphorylated to FDG-6-phosphate by hexokinase, which cannot be further metabolized, leading to intracellular accumulation proportional to glucose metabolism. It emits positrons detected by PET imaging.
NEUROLITE is a sodium channel blocker that stabilizes neuronal membranes and inhibits the release of excitatory neurotransmitters, thereby reducing neuronal excitability and seizure propagation.
5-10 mCi (185-370 MBq) intravenous injection, single dose for PET imaging.
300 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 110 minutes (range 100–120 minutes). This reflects clearance of unmetabolized FDG from plasma and is clinically relevant for imaging timing, as optimal image acquisition occurs 30–60 minutes post-injection to allow for target-to-background ratio maximization.
Terminal half-life: 12-15 hours; steady-state reached in 2-3 days
Primarily renal; approximately 90% of injected activity is excreted unchanged in urine within the first 2 hours post-injection. Less than 5% is eliminated via feces.
Renal: 70% unchanged; Biliary/Fecal: 15% as metabolites; 15% other
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical